The CDC is offering this grant to develop, improve, and implement advanced laboratory techniques utilizing next-generation sequencing (NGS) technologies. This grant is specifically for assessing severe combined immune deficiency (SCID) and other primary immunodeficiencies, serving as a vital second-tier test within state newborn screening laboratories. A core purpose is to thoroughly evaluate the practical potential of integrating NGS technologies into these settings. The results from this activity will be crucial for informing other state newborn screening laboratories about the feasibility and benefits of using NGS to accurately evaluate infants who screen positive for SCID and other primary immunodeficiencies. The ultimate goal of this initiative is to significantly enhance diagnostic precision and improve treatment outcomes for affected babies.
Opportunity ID: 273073
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-EH-15-002 |
| Funding Opportunity Title: | Development and validation of laboratory procedures using next generation sequencing technologies to assess genes causing severe combined immune deficiency (SCID) in state newborn screening laboratories |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.070 — Environmental Public Health and Emergency Response |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 6 |
| Posted Date: | Feb 04, 2015 |
| Last Updated Date: | Mar 06, 2015 |
| Original Closing Date for Applications: | Apr 06, 2015 |
| Current Closing Date for Applications: | Apr 06, 2015 |
| Archive Date: | May 06, 2015 |
| Estimated Total Program Funding: | $350,000 |
| Award Ceiling: | $350,000 |
| Award Floor: | $350,000 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | State governments,County governments,City or township governments,Special district governmentsIndependent school districts,Public and State controlled institutions of higher education,Native American tribal governments (Federally recognized),Public housing authorities/Indian housing authorities,Native American tribal organizations (other than Federally recognized tribal governments),Nonprofits having a 501(c)(3) status with the IRS, other than institutions ofhigher education,Nonprofits without 501(c)(3) status with the IRS, other than institutions ofhigher education,Private institutions of higher education,For profit organizations other than small businesses,Small businesses,Others (see text field entitled "Additional Information on Eligibility" for clarification),Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" |
Additional Information
| Agency Name: | Centers for Disease Control and Prevention – ERA |
| Description: | This FOA is to develop, improve, and implement laboratory techniques to assess babies born with severe combined immune deficiency (SCID) and other primary immunodeficiencies using next generation sequencing technologies as a second tier test in state newborn screening aboratories. CDC seeks to evaluate the potential of using next generation sequencing technologies in the state newborn screening laboratory setting. Results of this activity will be used to inform other state newborn screening laboratories about the feasibility of using next generation sequencing technologies in the state newborn screening laboratory setting to evaluate babies that screen positive for SCID and other primary mmunodeficiencies. The ultimate goal is to improve treatment outcomes for babies with SCID or other primary immunodeficiencies. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDC Technical Information Management Section (TIMS)
Procurement and Grants Office Telephone 770-488-2700 Email: PGOTIM@cdc.gov Hours: Monday – Friday, 7am – 4:30pm U.S. Eastern Standard Time Email:pgotim@cdc.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| The purpose of this FOA is to provide additional clarifying information based on questions received from potential applicants during the Pre-Application Conference Call or as a result of direct communication with the Scientific Program Official. A summary of the |
Mar 06, 2015 | |
| Jun 18, 2016 | ||
| Jun 18, 2016 | ||
| Development and validation of laboratory procedures using next generation sequencing technologies to assess genes causing severe combined immune deficiency (SCID) in state newborn screening laboratories. | Mar 06, 2015 | |
| Development and validation of laboratory procedures using next generation sequencing technologies to assess genes causing severe combined immune deficiency (SCID) in state newborn screening laboratories. | Feb 05, 2015 | |
| Development and validation of laboratory procedures using next generation sequencing technologies to assess genes causing severe combined immune deficiency (SCID) in state newborn screening laboratories. | Feb 05, 2015 | |
| Development and validation of laboratory procedures using next generation sequencing technologies to assess genes causing severe combined immune deficiency (SCID) in state newborn screening laboratories. | Feb 05, 2015 | |
| Feb 05, 2015 |
DISPLAYING: Synopsis 6
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-EH-15-002 |
| Funding Opportunity Title: | Development and validation of laboratory procedures using next generation sequencing technologies to assess genes causing severe combined immune deficiency (SCID) in state newborn screening laboratories |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.070 — Environmental Public Health and Emergency Response |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 6 |
| Posted Date: | Feb 04, 2015 |
| Last Updated Date: | Mar 06, 2015 |
| Original Closing Date for Applications: | Apr 06, 2015 |
| Current Closing Date for Applications: | Apr 06, 2015 |
| Archive Date: | May 06, 2015 |
| Estimated Total Program Funding: | $350,000 |
| Award Ceiling: | $350,000 |
| Award Floor: | $350,000 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | State governments,County governments,City or township governments,Special district governmentsIndependent school districts,Public and State controlled institutions of higher education,Native American tribal governments (Federally recognized),Public housing authorities/Indian housing authorities,Native American tribal organizations (other than Federally recognized tribal governments),Nonprofits having a 501(c)(3) status with the IRS, other than institutions ofhigher education,Nonprofits without 501(c)(3) status with the IRS, other than institutions ofhigher education,Private institutions of higher education,For profit organizations other than small businesses,Small businesses,Others (see text field entitled "Additional Information on Eligibility" for clarification),Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" |
Additional Information
| Agency Name: | Centers for Disease Control and Prevention – ERA |
| Description: | This FOA is to develop, improve, and implement laboratory techniques to assess babies born with severe combined immune deficiency (SCID) and other primary immunodeficiencies using next generation sequencing technologies as a second tier test in state newborn screening aboratories. CDC seeks to evaluate the potential of using next generation sequencing technologies in the state newborn screening laboratory setting. Results of this activity will be used to inform other state newborn screening laboratories about the feasibility of using next generation sequencing technologies in the state newborn screening laboratory setting to evaluate babies that screen positive for SCID and other primary mmunodeficiencies. The ultimate goal is to improve treatment outcomes for babies with SCID or other primary immunodeficiencies. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDC Technical Information Management Section (TIMS)
Procurement and Grants Office Telephone 770-488-2700 Email: PGOTIM@cdc.gov Hours: Monday – Friday, 7am – 4:30pm U.S. Eastern Standard Time Email:pgotim@cdc.gov |
DISPLAYING: Forecast 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | CDC-RFA-EH15-002 |
| Funding Opportunity Title: | Development and validation of laboratory procedures using next generation sequencing technologies to assess genes causing severe combined immune deficiency (SCID) in state newborn screening laboratories. |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.070 — Environmental Public Health and Emergency Response |
| Cost Sharing or Matching Requirement: | No |
| Version: | Forecast 2 |
| Posted Date: | Jun 18, 2016 |
| Last Updated Date: | Jun 18, 2016 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | – |
| Archive Date: | Apr 16, 2015 |
| Estimated Total Program Funding: | $350,000 |
| Award Ceiling: | $350,000 |
| Award Floor: | $350,000 |
Eligibility
| Eligible Applicants: | Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments Small businesses Special district governments Public and State controlled institutions of higher education County governments Public housing authorities/Indian housing authorities Private institutions of higher education City or township governments Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” Others (see text field entitled “Additional Information on Eligibility” for clarification) Native American tribal governments (Federally recognized) |
| Additional Information on Eligibility: | This FOA seeks research to develop, improve, and implement laboratory techniques to assess babies born with severe combined immune deficiency (SCID) using next generation sequencing technologies as a second tier test in state newborn screening laboraboratories. The newborn screening programs are administered by State Health Departments and results of this research need to be easily transitioned to State Health Departments for their use. Applicants must represent or be part of a coordinated partnership with an established state or territorial newborn screening program. |
Additional Information
| Agency Name: | – |
| Description: | Newborn screening programs test infants for diseases that require immediate medical treatment but are not apparent at birth. More than 4 million newborns are tested annually in the United States, and thousands of infants and children are saved from disability and death through early detection and treatment. Newborn screening practices, including the types of disorders for which newborns are screened, vary from state to state.   Severe combined immune deficiency (SCID) is a deadly disease that affects one in 40,000-100,000 infants and is treatable if detected early in life. In 2010, the Secretary’s Advisory Committee on Heritable Disorders in Newborn Screening and Children and the United States Secretary of Health and Human Services approved SCID as the 30th core condition on the Recommended Uniform Screening Panel, a list of disorders recommended for testing by every state newborn screening program in the United States. This FOA seeks research to develop, improve, and implement advanced genetic sequencing techniques for use in state newborn screening laboratories to assess babies born with SCID.  Research Objectives: This research project seeks to utilize current next generation sequencing technologies to develop second-tier methods to identify mutations in genes that cause SCID and other primary immunodeficiencies.  The goal is to expand state newborn screening laboratory capacity in the development and implementation of targeted next generation sequencing approaches for genes associated with SCID. Research activities will address all of the following: 1. Develop and validate robust next generation sequencing methods for accurate and timely delivery of results consistent with the high throughput needs of state newborn screening programs. The proposed method should be inclusive of genes known to cause SCID and other primary immunodeficiencies, with appropriate coverage, and be scalable to add new genes, as appropriate. 2. Ensure consistent high quality performance characteristics of the new method.  3. Partner with the CDC newborn screening laboratories to create quality assurance materials. 4. Partner with medical specialists to assure appropriate impact on diagnosis and treatment.   5. Provide education and training for laboratory scientists, healthcare providers, state newborn screening program officials, and primary care physicians about state newborn screen tests for mutations in SCID genes. 6. Conduct a retrospective evaluation of screened positive SCID samples internally or in collaboration with partner state programs to validate the method and evaluate mutations in genes that may cause SCID and other primary immunodeficiencies.  |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
–
Email:SFN8@cdc.gov |
DISPLAYING: Forecast 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | CDC-RFA-EH15-002 |
| Funding Opportunity Title: | Research to develop and implement second tier DNA-based sequence analysis of genetic targets for severe combined immune deficiency (SCID) in state newborn screening laboratories |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.070 — Environmental Public Health and Emergency Response |
| Cost Sharing or Matching Requirement: | No |
| Version: | Forecast 1 |
| Posted Date: | Jun 18, 2016 |
| Last Updated Date: | Jun 18, 2016 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | – |
| Archive Date: | Apr 16, 2015 |
| Estimated Total Program Funding: | $350,000 |
| Award Ceiling: | $350,000 |
| Award Floor: | $350,000 |
Eligibility
| Eligible Applicants: | State governments |
| Additional Information on Eligibility: | This FOA seeks research to advance analysis of newborn blood screening tests to improve early identification of infants with SCID. These testing programs are administered by State Health Departments and results need to be easily transitioned to their use. |
Additional Information
| Agency Name: | – |
| Description: | Newborn screening programs test infants for diseases that require immediate medical treatment but are not apparent at birth. More than 4 million newborns are tested annually in the United States, and thousands of infants and children are saved from disability and death through early detection and treatment. Newborn screening practices, including the types of disorders for which newborns are screened, vary from state to state.  SCID is a deadly disease that affects one in 40,000-100,000 infants and is treatable if detected early in life. In 2010, the Secretary’s Advisory Committee on Heritable Disorders in Newborn Screening and Children and the United States Secretary of Health and Human Services approved SCID as the 30th core condition on the Recommended Uniform Screening Panel, a list of disorders recommended for testing by every newborn screening program in the United States.  Research Objectives: This research project seeks to utilize current next generation sequencing technologies to develop second-tier methods to identify mutations in SCID genes.  The goal is to expand newborn screening laboratory capacity in the development and implementation of targeted next generation sequencing approaches for genes associated with SCID.  Research activities will address the following: 1.     Develop and validate a robust sequencing method for accurate and timely delivery of results consistent with the high throughput needs of newborn screening programs. 2.     Ensure consistent high quality performance characteristics of the new method  3.     Partner with the CDC Newborn Screening laboratories to establish a repository of known SCID gene mutations and participate in beta-testing the utility of newly developed quality assurance materials 4.     Develop an infrastructure for screening and reporting SCID gene sequencing results 5.     Partner with medical specialists to define the genotype / phenotype correlation and its impact on diagnosis and treatment   6.     Provide education and training for laboratory scientists, healthcare providers, NBS program officials, and primary care physicians about NBS tests for mutations in SCID genes |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
–
Email:SFN8@cdc.gov |
DISPLAYING: Synopsis 5
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-EH-15-002 |
| Funding Opportunity Title: | Development and validation of laboratory procedures using next generation sequencing technologies to assess genes causing severe combined immune deficiency (SCID) in state newborn screening laboratories |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.070 — Environmental Public Health and Emergency Response |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 5 |
| Posted Date: | Mar 06, 2015 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Apr 06, 2015 |
| Archive Date: | May 06, 2015 |
| Estimated Total Program Funding: | $350,000 |
| Award Ceiling: | $350,000 |
| Award Floor: | $350,000 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | State governments,County governments,City or township governments,Special district governments Independent school districts,Public and State controlled institutions of higher education,Native American tribal governments (Federally recognized),Public housing authorities/Indian housing authorities,Native American tribal organizations (other than Federally recognized tribal governments),Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Nonprofits without 501(c)(3) status with the IRS, other than institutions of higher education,Private institutions of higher education,For profit organizations other than small businesses,Small businesses,Others (see text field entitled "Additional Information on Eligibility" for clarification),Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" |
Additional Information
| Agency Name: | Centers for Disease Control and Prevention – ERA |
| Description: | This FOA is to develop, improve, and implement laboratory techniques to assess babies born with severe combined immune deficiency (SCID) and other primary immunodeficiencies using next generation sequencing technologies as a second tier test in state newborn screening aboratories. CDC seeks to evaluate the potential of using next generation sequencing technologies in the state newborn screening laboratory setting. Results of this activity will be used to inform other state newborn screening laboratories about the feasibility of using next generation sequencing technologies in the state newborn screening laboratory setting to evaluate babies that screen positive for SCID and other primary mmunodeficiencies. The ultimate goal is to improve treatment outcomes for babies with SCID or other primary immunodeficiencies. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDC Technical Information Management Section (TIMS)
Procurement and Grants Office Telephone 770-488-2700 Email: PGOTIM@cdc.gov Hours: Monday – Friday, 7am – 4:30pm U.S. Eastern Standard Time Email:pgotim@cdc.gov |
DISPLAYING: Synopsis 4
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-EH-15-002 |
| Funding Opportunity Title: | Development and validation of laboratory procedures using next generation sequencing technologies to assess genes causing severe combined immune deficiency (SCID) in state newborn screening laboratories |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.070 — Environmental Public Health and Emergency Response |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 4 |
| Posted Date: | Feb 05, 2015 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Apr 06, 2015 |
| Archive Date: | May 06, 2015 |
| Estimated Total Program Funding: | $350,000 |
| Award Ceiling: | $350,000 |
| Award Floor: | $350,000 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | State governments,County governments,City or township governments,Special district governments Independent school districts,Public and State controlled institutions of higher education,Native American tribal governments (Federally recognized),Public housing authorities/Indian housing authorities,Native American tribal organizations (other than Federally recognized tribal governments),Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Nonprofits without 501(c)(3) status with the IRS, other than institutions of higher education,Private institutions of higher education,For profit organizations other than small businesses,Small businesses,Others (see text field entitled "Additional Information on Eligibility" for clarification),Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" |
Additional Information
| Agency Name: | Centers for Disease Control and Prevention – ERA |
| Description: | This FOA is to develop, improve, and implement laboratory techniques to assess babies born with severe combined immune deficiency (SCID) and other primary immunodeficiencies using next generation sequencing technologies as a second tier test in state newborn screening aboratories. CDC seeks to evaluate the potential of using next generation sequencing technologies in the state newborn screening laboratory setting. Results of this activity will be used to inform other state newborn screening laboratories about the feasibility of using next generation sequencing technologies in the state newborn screening laboratory setting to evaluate babies that screen positive for SCID and other primary mmunodeficiencies. The ultimate goal is to improve treatment outcomes for babies with SCID or other primary immunodeficiencies. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDC Technical Information Management Section (TIMS)
Procurement and Grants Office Telephone 770-488-2700 Email: PGOTIM@cdc.gov Hours: Monday – Friday, 7am – 4:30pm U.S. Eastern Standard Time Email:pgotim@cdc.gov |
DISPLAYING: Synopsis 3
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-EH-15-002 |
| Funding Opportunity Title: | Development and validation of laboratory procedures using next generation sequencing technologies to assess genes causing severe combined immune deficiency (SCID) in state newborn screening laboratorie |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.070 — Environmental Public Health and Emergency Response |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Feb 05, 2015 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Apr 06, 2015 |
| Archive Date: | May 06, 2015 |
| Estimated Total Program Funding: | $350,000 |
| Award Ceiling: | $350,000 |
| Award Floor: | $350,000 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | State governments,County governments,City or township governments,Special district governments Independent school districts,Public and State controlled institutions of higher education,Native American tribal governments (Federally recognized),Public housing authorities/Indian housing authorities,Native American tribal organizations (other than Federally recognized tribal governments),Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Nonprofits without 501(c)(3) status with the IRS, other than institutions of higher education,Private institutions of higher education,For profit organizations other than small businesses,Small businesses,Others (see text field entitled "Additional Information on Eligibility" for clarification),Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" |
Additional Information
| Agency Name: | Centers for Disease Control and Prevention – ERA |
| Description: | This FOA is to develop, improve, and implement laboratory techniques to assess babies born with severe combined immune deficiency (SCID) and other primary immunodeficiencies using next generation sequencing technologies as a second tier test in state newborn screening aboratories. CDC seeks to evaluate the potential of using next generation sequencing technologies in the state newborn screening laboratory setting. Results of this activity will be used to inform other state newborn screening laboratories about the feasibility of using next generation sequencing technologies in the state newborn screening laboratory setting to evaluate babies that screen positive for SCID and other primary mmunodeficiencies. The ultimate goal is to improve treatment outcomes for babies with SCID or other primary immunodeficiencies. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDC Technical Information Management Section (TIMS)
Procurement and Grants Office Telephone 770-488-2700 Email: PGOTIM@cdc.gov Hours: Monday – Friday, 7am – 4:30pm U.S. Eastern Standard Time Email:pgotim@cdc.gov |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-EH-15-002 |
| Funding Opportunity Title: | Development and validation of laboratory procedures using next generation sequencing technologies to assess genes causing severe combined immune deficiency (SCID) in state newborn screening laboratorie |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.070 — Environmental Public Health and Emergency Response |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Feb 05, 2015 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Apr 06, 2015 |
| Archive Date: | May 06, 2015 |
| Estimated Total Program Funding: | $350,000 |
| Award Ceiling: | $350,000 |
| Award Floor: | $350,000 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | State governments,County governments,City or township governments,Special district governments Independent school districts,Public and State controlled institutions of higher education,Native American tribal governments (Federally recognized),Public housing authorities/Indian housing authorities,Native American tribal organizations (other than Federally recognized tribal governments),Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Nonprofits without 501(c)(3) status with the IRS, other than institutions of higher education,Private institutions of higher education,For profit organizations other than small businesses,Small businesses,Others (see text field entitled "Additional Information on Eligibility" for clarification),Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" |
Additional Information
| Agency Name: | Centers for Disease Control and Prevention – ERA |
| Description: | This FOA is to develop, improve, and implement laboratory techniques to assess babies born with severe combined immune deficiency (SCID) and other primary immunodeficiencies using next generation sequencing technologies as a second tier test in state newborn screening aboratories. CDC seeks to evaluate the potential of using next generation sequencing technologies in the state newborn screening laboratory setting. Results of this activity will be used to inform other state newborn screening laboratories about the feasibility of using next generation sequencing technologies in the state newborn screening laboratory setting to evaluate babies that screen positive for SCID and other primary mmunodeficiencies. The ultimate goal is to improve treatment outcomes for babies with SCID or other primary immunodeficiencies. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDC Technical Information Management Section (TIMS)
Procurement and Grants Office Telephone 770-488-2700 Email: PGOTIM@cdc.gov Hours: Monday – Friday, 7am – 4:30pm U.S. Eastern Standard Time Email:pgotim@cdc.gov |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-EH-15-002 |
| Funding Opportunity Title: | Development and validation of laboratory procedures using next generation sequencing technologies to |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.070 — Environmental Public Health and Emergency Response |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Feb 05, 2015 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Apr 06, 2015 |
| Archive Date: | May 06, 2015 |
| Estimated Total Program Funding: | $350,000 |
| Award Ceiling: | $350,000 |
| Award Floor: | $350,000 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | State governments,County governments,City or township governments,Special district governments Independent school districts,Public and State controlled institutions of higher education,Native American tribal governments (Federally recognized),Public housing authorities/Indian housing authorities,Native American tribal organizations (other than Federally recognized tribal governments),Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Nonprofits without 501(c)(3) status with the IRS, other than institutions of higher education,Private institutions of higher education,For profit organizations other than small businesses,Small businesses,Others (see text field entitled "Additional Information on Eligibility" for clarification),Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" |
Additional Information
| Agency Name: | Centers for Disease Control and Prevention – ERA |
| Description: | This FOA is to develop, improve, and implement laboratory techniques to assess babies born with severe combined immune deficiency (SCID) and other primary immunodeficiencies using next generation sequencing technologies as a second tier test in state newborn screening aboratories. CDC seeks to evaluate the potential of using next generation sequencing technologies in the state newborn screening laboratory setting. Results of this activity will be used to inform other state newborn screening laboratories about the feasibility of using next generation sequencing technologies in the state newborn screening laboratory setting to evaluate babies that screen positive for SCID and other primary mmunodeficiencies. The ultimate goal is to improve treatment outcomes for babies with SCID or other primary immunodeficiencies. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDC Technical Information Management Section (TIMS)
Procurement and Grants Office Telephone 770-488-2700 Email: PGOTIM@cdc.gov Hours: Monday – Friday, 7am – 4:30pm U.S. Eastern Standard Time Email:pgotim@cdc.gov |
Related Documents
Folder 273073 Full Announcement-1 -> rfa-eh15-002 amend 1.pdf
Packages
| Agency Contact Information: | CDC Technical Information Management Section (TIMS) Procurement and Grants Office Telephone 770-488-2700 Email: PGOTIM@cdc.gov Hours: Monday – Friday, 7am – 4:30pm U.S. Eastern Standard Time Email: pgotim@cdc.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.070 | RFA-EH-15-002 | Development and validation of laboratory procedures using next generation sequencing technologies to assess genes causing severe combined immune deficiency (SCID) in state newborn screening laboratories | PKG00213344 | Feb 04, 2015 | Apr 06, 2015 | View |
Package 1
Mandatory forms
273073 RR_SF424_2_0-2.0.pdf
273073 PHS398_ResearchPlan_2_0-2.0.pdf
273073 PHS398_CoverPageSupplement_2_0-2.0.pdf
273073 RR_Budget_1_3-1.3.pdf
273073 RR_KeyPersonExpanded_2_0-2.0.pdf
273073 RR_OtherProjectInfo_1_3-1.3.pdf
273073 PerformanceSite_2_0-2.0.pdf
Optional forms
273073 PlannedReport-1.0.pdf
273073 PHS398_CumulativeInclusionReport-1.0.pdf
273073 RR_SubawardBudget30_1_3-1.3.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
